David Long Named CFO of Cynosure

David Long has been named Chief Financial Officer of Cynosure effective immediately. With more than 25 years of global finance experience and a proven track record of success, the Cynosure reports David Long will help accelerate the company’s business transformation and growth plans under the new leadership of Chief Executive Officer and former Hershey and Unilever executive, Todd Tillemans.

Mr. Tillemans said, “This is an exciting time as we look to position Cynosure for long-term sustainable growth and we’re thrilled to have David join the team. He is a highly respected finance leader who will be invaluable as we prioritize investments in new innovation to drive our customers’ businesses, and ultimately provide patients around the globe with best-in-class technology and service.”

Until recently, David Long served as CFO at Corindus Vascular Robotics, Inc. where he led numerous commercial and operational improvements, successfully brought the company public and, ultimately, navigated its strategic sale to Siemens. Prior to his time at Corindus, Long spent nearly a decade at Thermo Fisher Scientific, where he held the position of Vice President of Finance of the Laboratory Equipment Division. Long also served as an adjunct professor in the Department of Accountancy at Bentley University.

“I’m excited to join such a strong team of leaders,” Long said. “I’m eager to get to work and make an impact alongside the leadership team to ensure we remain positioned for continued success and deliver the market-leading technology clinicians and consumers rely on from Cynosure.”

David Long holds a Master of Public Administration from the University of Pennsylvania and a Bachelor of Science in Finance from the University of Massachusetts.

SourceCynosure

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version